Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy

Area of Science:

• Infectious Diseases
• Pediatrics
• Microbiology

Background:

• Acute otitis media (AOM) is a common childhood infection often caused by bacteria like Streptococcus pneumoniae.
• Antibiotic resistance is a growing concern in AOM treatment, necessitating evaluation of alternative therapies.
• Cefdinir, a third-generation cephalosporin, has demonstrated efficacy against common AOM pathogens.

Purpose of the Study:

• To assess the clinical and microbiologic effectiveness of a 5-day cefdinir regimen for treating AOM.
• To evaluate cefdinir's efficacy against specific pathogens, including penicillin-resistant Streptococcus pneumoniae and beta-lactamase-producing organisms.
• To determine cefdinir's suitability as a second-line antibiotic for AOM.

Main Methods:

• An open-label, noncomparative trial was conducted in a primary care setting.
• Children aged 6 months to 12 years with tympanocentesis-documented AOM were enrolled.
• Patients received cefdinir 7 mg/kg twice daily for 5 days, with clinical and microbiologic assessments.

Main Results:

• The study identified Streptococcus pneumoniae (51.5%), Haemophilus influenzae (32.8%), and Moraxella catarrhalis (11.2%) as primary pathogens.
• Clinical cure rates at the end of therapy were 73% (microbiologically evaluable) and 77.4% (clinically evaluable).
• Presumptive eradication rates for penicillin-intermediate and -resistant S. pneumoniae were 72.7% and 50%, respectively. Diarrhea was the most common adverse reaction (11%).

Conclusions:

• A 5-day cefdinir regimen is effective in eradicating common AOM pathogens, including resistant strains.
• Cefdinir demonstrates efficacy against intermediate penicillin-resistant S. pneumoniae and beta-lactamase-producing organisms.
• Cefdinir is a viable second-line antibiotic option for managing acute otitis media.